Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lisa E. Hensley is active.

Publication


Featured researches published by Lisa E. Hensley.


American Journal of Pathology | 2003

Pathogenesis of Ebola Hemorrhagic Fever in Cynomolgus Macaques: Evidence that Dendritic Cells Are Early and Sustained Targets of Infection

Thomas W. Geisbert; Lisa E. Hensley; Tom Larsen; Howard A. Young; Douglas S. Reed; Joan B. Geisbert; Dana P. Scott; Elliott Kagan; Peter B. Jahrling; Kelly J. Davis

Ebola virus (EBOV) infection causes a severe and fatal hemorrhagic disease that in many ways appears to be similar in humans and nonhuman primates; however, little is known about the development of EBOV hemorrhagic fever. In the present study, 21 cynomolgus monkeys were experimentally infected with EBOV and examined sequentially over a 6-day period to investigate the pathological events of EBOV infection that lead to death. Importantly, dendritic cells in lymphoid tissues were identified as early and sustained targets of EBOV, implicating their important role in the immunosuppression characteristic of EBOV infections. Bystander lymphocyte apoptosis, previously described in end-stage tissues, occurred early in the disease-course in intravascular and extravascular locations. Of note, apoptosis and loss of NK cells was a prominent finding, suggesting the importance of innate immunity in determining the fate of the host. Analysis of peripheral blood mononuclear cell gene expression showed temporal increases in tumor necrosis factor-related apoptosis-inducing ligand and Fas transcripts, revealing a possible mechanism for the observed bystander apoptosis, while up-regulation of NAIP and cIAP2 mRNA suggest that EBOV has evolved additional mechanisms to resist host defenses by inducing protective transcripts in cells that it infects. The sequence of pathogenetic events identified in this study should provide new targets for rational prophylactic and chemotherapeutic interventions.


American Journal of Pathology | 2003

Pathogenesis of Ebola Hemorrhagic Fever in Primate Models: Evidence that Hemorrhage Is Not a Direct Effect of Virus-Induced Cytolysis of Endothelial Cells

Thomas W. Geisbert; Howard A. Young; Peter B. Jahrling; Kelly J. Davis; Tom Larsen; Elliott Kagan; Lisa E. Hensley

Ebola virus (EBOV) infection causes a severe and often fatal hemorrhagic disease in humans and nonhuman primates. Whether infection of endothelial cells is central to the pathogenesis of EBOV hemorrhagic fever (HF) remains unknown. To clarify the role of endothelial cells in EBOV HF, we examined tissues of 21 EBOV-infected cynomolgus monkeys throughout time, and also evaluated EBOV infection of primary human umbilical vein endothelial cells and primary human lung-derived microvascular endothelial cells in vitro. Results showed that endothelial cells were not early cellular targets of EBOV in vivo, as viral replication was not consistently observed until day 5 after infection, a full day after the onset of disseminated intravascular coagulation. Moreover, the endothelium remained relatively intact even at terminal stages of disease. Although human umbilical vein endothelial cells and human lung-derived microvascular endothelial cells were highly permissive to EBOV replication, significant cytopathic effects were not observed. Analysis of host cell gene response at 24 to 144 hours after infection showed some evidence of endothelial cell activation, but changes were unremarkable considering the extent of viral replication. Together, these data suggest that coagulation abnormalities associated with EBOV HF are not the direct result of EBOV-induced cytolysis of endothelial cells, and are likely triggered by immune-mediated mechanisms.


Archives of Virology | 2013

Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae.

Jens H. Kuhn; Yiming Bao; Sina Bavari; Stephan Becker; Steven B. Bradfute; J. Rodney Brister; Alexander Bukreyev; Yíngyún Caì; Kartik Chandran; Robert A. Davey; Olga Dolnik; John M. Dye; Sven Enterlein; Jean-Paul Gonzalez; Pierre Formenty; Alexander N. Freiberg; Lisa E. Hensley; Anna N. Honko; Georgy M. Ignatyev; Peter B. Jahrling; Karl M. Johnson; Hans-Dieter Klenk; Gary P. Kobinger; Matthew G. Lackemeyer; Eric Leroy; Mark S. Lever; Loreen L. Lofts; Elke Mühlberger; Sergey V. Netesov; Gene G. Olinger

The International Committee on Taxonomy of Viruses (ICTV) organizes the classification of viruses into taxa, but is not responsible for the nomenclature for taxa members. International experts groups, such as the ICTV Study Groups, recommend the classification and naming of viruses and their strains, variants, and isolates. The ICTV Filoviridae Study Group has recently introduced an updated classification and nomenclature for filoviruses. Subsequently, and together with numerous other filovirus experts, a consistent nomenclature for their natural genetic variants and isolates was developed that aims at simplifying the retrieval of sequence data from electronic databases. This is a first important step toward a viral genome annotation standard as sought by the US National Center for Biotechnology Information (NCBI). Here, this work is extended to include filoviruses obtained in the laboratory by artificial selection through passage in laboratory hosts. The previously developed template for natural filovirus genetic variant naming ( ///-) is retained, but it is proposed to adapt the type of information added to each field for laboratory animal-adapted variants. For instance, the full-length designation of an Ebola virus Mayinga variant adapted at the State Research Center for Virology and Biotechnology “Vector” to cause disease in guinea pigs after seven passages would be akin to “Ebola virus VECTOR/C.porcellus-lab/COD/1976/Mayinga-GPA-P7”. As was proposed for the names of natural filovirus variants, we suggest using the full-length designation in databases, as well as in the method section of publications. Shortened designations (such as “EBOV VECTOR/C.por/COD/76/May-GPA-P7”) and abbreviations (such as “EBOV/May-GPA-P7”) could be used in the remainder of the text depending on how critical it is to convey information contained in the full-length name. “EBOV” would suffice if only one EBOV strain/variant/isolate is addressed.


Science | 2012

Emerging Disease or Diagnosis

Stephen K. Gire; Matthew Stremlau; Kristian G. Andersen; Stephen F. Schaffner; Zach Bjornson; Kathleen H. Rubins; Lisa E. Hensley; Joseph B. McCormick; Eric S. Lander; Robert F. Garry; Christian T. Happi; Pardis C. Sabeti

Some viral infections may not represent emerging diseases, but improved detection and diagnosis of common diseases. Outbreaks this year of the deadly and highly contagious Ebola and Marburg viruses in the Democratic Republic of Congo and Uganda and Lassa virus in Nigeria raised concerns about possible epidemic spread of these hemorrhagic fevers. These pathogens seemed to appear out of nowhere around the middle of the 20th century: Marburg virus in 1967, Lassa virus in 1969, and Ebola virus in 1976. By the early 1990s, public health concerns were crystallized in a landmark report (1) that was the first to popularize the concept of “emerging pathogens” (fig. S1). But could “emerging diagnosis” explain the rise in appearance of hemorrhagic fevers caused by these pathogens? Recent epidemiologic and genetic studies of Lassa and Ebola fevers suggest that these diseases may have widespread prevalence and ancient origins. They raise the possibility that some viral infections may reflect “emerging diagnoses” of diseases that are circulating more widely than thought, with an emerging character primarily a matter of improved detection of the culprit pathogens.


BMC Genomics | 2012

High depth, whole-genome sequencing of cholera isolates from Haiti and the Dominican Republic

Rachel Sealfon; Stephen K. Gire; Crystal N. Ellis; Stephen B. Calderwood; Firdausi Qadri; Lisa E. Hensley; Manolis Kellis; Edward T. Ryan; Regina C. LaRocque; Jason B. Harris; Pardis C. Sabeti

BackgroundWhole-genome sequencing is an important tool for understanding microbial evolution and identifying the emergence of functionally important variants over the course of epidemics. In October 2010, a severe cholera epidemic began in Haiti, with additional cases identified in the neighboring Dominican Republic. We used whole-genome approaches to sequence four Vibrio cholerae isolates from Haiti and the Dominican Republic and three additional V. cholerae isolates to a high depth of coverage (>2000x); four of the seven isolates were previously sequenced.ResultsUsing these sequence data, we examined the effect of depth of coverage and sequencing platform on genome assembly and identification of sequence variants. We found that 50x coverage is sufficient to construct a whole-genome assembly and to accurately call most variants from 100 base pair paired-end sequencing reads. Phylogenetic analysis between the newly sequenced and thirty-three previously sequenced V. cholerae isolates indicates that the Haitian and Dominican Republic isolates are closest to strains from South Asia. The Haitian and Dominican Republic isolates form a tight cluster, with only four variants unique to individual isolates. These variants are located in the CTX region, the SXT region, and the core genome. Of the 126 mutations identified that separate the Haiti-Dominican Republic cluster from the V. cholerae reference strain (N16961), 73 are non-synonymous changes, and a number of these changes cluster in specific genes and pathways.ConclusionsSequence variant analyses of V. cholerae isolates, including multiple isolates from the Haitian outbreak, identify coverage-specific and technology-specific effects on variant detection, and provide insight into genomic change and functional evolution during an epidemic.


Archive | 2006

siRNA SILENCING OF FILOVIRUS GENE EXPRESSION

Ian Maclachlan; Vandana Sood; Thomas W. Geisbert; Lisa E. Hensley; Elliott Kagan


Archive | 2002

Filovirus Pathogenesis in Nonhuman Primates

Thomas W. Geisbert; Peter B. Jahrling; Tom Larsen; Kelly J. Davis; Lisa E. Hensley


Clinical Microbiology and Infectious Diseases (CMID) | 2017

Experiences of outbreak laboratory management in the Ebola Disease outbreak in West-Africa 2014-2015 (Forthcoming)

Manfred Weidmann; Daniel Bailey; Lamballerie Xavier de; Antonino DiCaro; Stephane Doyon; Ousmane Faye; Laurence Flevaud; A Foomsgard; Lisa E. Hensley; Lamine Koivogui; Kelfala Konneh; Marion P Koopmans; N'Faly Magassouba; Ali Mirazimi; Donatus I Adomeh


Archive | 2016

Detecting Virus Exposure During the Pre Symptomatic Incubation Period Using Physiological Data (with Supplementary Materials)

Albert Swiston; Lauren Milechin; Shakti Davis; Tejash Patel; Mark Hernandez; Greg Ciccarelli; Steven Schwartz; Lisa E. Hensley; Arthur J. Goff; John Trefry; Catherine Cabrera; Jack G. Fleischman; Albert Reuther; Franco Rossi; Anna N. Honko; William D. Pratt


Archive | 2015

Supplementary Materials for A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity

Lisa M. Johansen; Lisa Evans DeWald; Charles J. Shoemaker; Benjamin G. Hoffstrom; Calli M. Lear-Rooney; Andrea Stossel; Elizabeth A. Nelson; Sue E. Delos; James A. Simmons; Jill M. Grenier; Laura T. Pierce; Hassan Pajouhesh; Joseph Lehar; Lisa E. Hensley; Pamela J. Glass; Judith M. White; Gene G. Olinger

Collaboration


Dive into the Lisa E. Hensley's collaboration.

Top Co-Authors

Avatar

Elliott Kagan

Uniformed Services University of the Health Sciences

View shared research outputs
Top Co-Authors

Avatar

Peter B. Jahrling

United States Army Medical Research Institute of Infectious Diseases

View shared research outputs
Top Co-Authors

Avatar

Gene G. Olinger

United States Army Medical Research Institute of Infectious Diseases

View shared research outputs
Top Co-Authors

Avatar

Ian Maclachlan

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Anna N. Honko

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Howard A. Young

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Vandana Sood

Alnylam Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Adam Judge

Alnylam Pharmaceuticals

View shared research outputs
Researchain Logo
Decentralizing Knowledge